Omslagafbeelding van de show tHEORetically Speaking

tHEORetically Speaking

Podcast door HealthEconomics.com

Engels

Technologie en Wetenschap

Tijdelijke aanbieding

2 maanden voor € 1

Daarna € 9,99 / maandElk moment opzegbaar.

  • 20 uur luisterboeken / maand
  • Podcasts die je alleen op Podimo hoort
  • Gratis podcasts
Begin hier

Over tHEORetically Speaking

Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/

Alle afleveringen

86 afleveringen

aflevering Weekly News Roundup — Wegovy Pill’s Historic Debut, Lilly’s Manufacturing Expansion, and Robotic GI Breakthroughs artwork

Weekly News Roundup — Wegovy Pill’s Historic Debut, Lilly’s Manufacturing Expansion, and Robotic GI Breakthroughs

This week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s oral Wegovy pill shattering market expectations with $355 million in first-quarter sales, [https://healtheconomics.com/novos-wegovy-pill-shatters-expectations-with-1-million-patients-and-355m-in-sales/] and Eli Lilly’s massive $4.5 billion investment to expand its manufacturing footprint in Indiana [https://healtheconomics.com/eli-lilly-expands-indiana-manufacturing-footprint-with-4-5-billion-investment/]. We also explore Neptune Medical’s Triton GI robot reaching major clinical milestones in its first-in-human trials [https://healtheconomics.com/neptune-medicals-gi-robot-hits-major-milestones-in-clinical-debut/].  Tune in for this concise recap of these pivotal industry updates!

8 mei 2026 - 3 min
aflevering Weekly News Roundup — Real-Time Clinical Trials, Canadian Breast Cancer Standards, and FDA Data Integrity Concerns artwork

Weekly News Roundup — Real-Time Clinical Trials, Canadian Breast Cancer Standards, and FDA Data Integrity Concerns

This week’s tHEORetically Speaking News Roundup covers the FDA’s new real-time clinical trial initiative utilizing AI for faster drug development [https://healtheconomics.com/fda-launches-real-time-clinical-trial-initiative-to-accelerate-drug-development/], and Breast Cancer Canada’s new unified national recommendations to eliminate regional disparities in care [https://healtheconomics.com/breast-cancer-canada-real-canadian-breast-cancer-alliance-establish-national-recommendations-for-breast-cancer/]. We also break down the FDA’s proposal to withdraw Amgen’s Tavneos over data integrity issues and safety concerns. [https://healtheconomics.com/fda-proposes-withdrawal-of-amgens-tavneos-over-clinical-trial-data-integrity-issues/] Register for the WODC USA here: https://www.terrapinn.com/WODC/US/2026/HealthEconomics [https://www.terrapinn.com/WODC/US/2026/HealthEconomics] Use code HE25 for an extra 25% off your registration fee!

1 mei 2026 - 4 min
aflevering Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal artwork

Weekly News Roundup — PhRMA Leadership Transition, The ICHRA Shift, and MDUFA VI Preliminary Deal

This week’s tHEORetically Speaking News Roundup covers Steve Ubl’s planned departure from PhRMA after a decade of navigating the industry through landmark legislative shifts [https://healtheconomics.com/steve-ubl-to-step-down-as-longest-serving-ceo-of-phrma/], and the growing momentum of ICHRAs as employers move toward "defined contribution" healthcare models [https://healtheconomics.com/the-ichra-shift-insurance-growth-meets-market-volatility/]. We also break down the preliminary MDUFA VI agreement [https://healtheconomics.com/fda-and-medtech-industry-reach-preliminary-mdufa-vi-agreement/], which signals a major hiring push at the FDA and a new "America-First" fee structure for medtech.  Tune in for this concise recap of these pivotal industry updates!

10 apr 2026 - 3 min
aflevering Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock artwork

Weekly News Roundup — Medtech Mega Deals, EU Regulatory Delays, and Global Supply Chain Shock

This week’s tHEORetically Speaking News Roundup covers Abbott’s $21 billion acquisition of Exact Sciences, signaling a major expansion in cancer diagnostics [https://healtheconomics.com/abbott-finalizing-21-billion-acquisition-of-exact-sciences/], and Boehringer Ingelheim’s concerns over Europe’s slowing regulatory timelines compared to the U.S. [https://healtheconomics.com/boehringer-ingelheim-flags-europes-regulatory-delays-as-u-s-drug-launches-accelerate/]We also break down a global supply chain shock triggered by the Strait of Hormuz closure.  [https://healtheconomics.com/boehringer-ingelheim-flags-europes-regulatory-delays-as-u-s-drug-launches-accelerate/] Tune in for this concise recap of these pivotal industry updates!

27 mrt 2026 - 2 min
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Makkelijk in gebruik!
App ziet er mooi uit, navigatie is even wennen maar overzichtelijk.

Kies je abonnement

Meest populair

Tijdelijke aanbieding

Premium

20 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

2 maanden voor € 1
Daarna € 9,99 / maand

Begin hier

Premium Plus

Onbeperkt luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 7 dagen gratis
Daarna € 13,99 / maand

Probeer gratis

Alleen bij Podimo

Populaire luisterboeken

Begin hier

2 maanden voor € 1. Daarna € 9,99 / maand. Elk moment opzegbaar.